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Metabolism and pharmacokinetics of the anti-tumour agent 2,3,5-
trimethyl-6-(3-pyridylmethyl)1,4-benzoquinone (CV-6504)
H J Hussey and M J Tisdale
Pharmaceutical Sciences Institute, Aston University, Birmingham B4 7ET, UK.
Summary 2,3,5-Trimethyl-6-(3-pyridylmethyl)1,4-benzoquinone (CV-6504) is an effective inhibitor of the
growth of established murine adenocarcinomas (MACs) and is shortly to enter clinical investigation. When
administered to mice bearing the MAC16 tumour, CV-6504 rapidly disappeared from the plasma and tissues
and there was an accumulation of the sulphate and glucuronide metabolites. After 24 h, the concentration of
free CV-6504 in the tumour (3.3 gM) was higher than that in the liver (0.24 /M) and equal to the IC50 value for
the inhibition of the growth of MAC16 cells in vitro (3 pM). The concentration of glucuronide and sulphate
metabolites in both tumour and liver decreased with time. Both the MAC16 tumour and the liver possessed
similar fl-glucuronidase activity, which could account for the accumulation of free CV-6504. Although the
sulphate and glucuronide conjugates of CV-6504 were ineffective inhibitors of the growth of MAC13 cells in
vitro at concentrations up to 100 gM, in vivo at a concentration of 50 mg kg-' day-' the conjugates produced
a similar anti-tumour effect to CV-6504 at a concentration of 5 mg kg-} day-l. The MAC13 tumour possessed
both ,B-glucuronidase and sulphatase activity capable of converting the sulphate and glucuronide conjugates to
free CV-6504. Using MAC13 cells ex vivo, CV-6504 inhibited conversion of arachidonic acid to 5-, 12- and 15-
hydroxyeicosatetraenoic acids (HETE). The percentage reduction in formation of 12- and 15-HETE exceeded
that of 5-HETE. Inhibition of HETE formation may be responsible for the anti-tumour activity of CV-6504.
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Products of metabolism of the polyunsaturated fatty acids
(PUFAs), arachidonic (AA) or linoleic (LA) acid, through
the lipoxygenase pathways have been shown to stimulate cell
proliferation (Bandyopadhyay et al., 1988) and may also act
as intermediaries in the mitogenic signalling by growth
factors, such as epidermal growth factor (EGF) (Glasgow
and Eling, 1990). Linoleic acid has been shown to induce
DNA synthesis, c-fos, c-jun and c-myc mRNA expression and
mitogen-activated protein kinase activation in vascular
smooth muscle cells, and this effect was blocked by
nordihydroguairetic acid, a potent inhibitor of the lipox-
ygenase system (Rao et al., 1995). Lipoxygenase inhibitors
have also been shown to inhibit the growth of both rat (Lee
and Ip, 1992) and mouse (Buckman et al., 1991) mammary
tumour cells and HL60 human leukaemia cells (Simon et al.,
1992).
Our own studies have identified the 5-lipoxygenase
inhibitor (Ohkawa et al., 1991a), 2,3,5-trimethyl-6-(3-pyridyl-
methyl)1,4-benzoquinone (CV-6504), as an effective inhibitor
of the growth of established murine adenocarcinomas (MAC)
in vivo with a therapeutic index of at least 10 (Hussey et al.,
1996). Such tumours are generally refractory to standard
cytotoxic agents, suggesting a novel mechanism of tumour
inhibition, and this agent is shortly to undergo clinical
evaluation.
CV-6504 undergoes rapid reduction by two-electron
donating enzymes, such as DT-diaphorase, and the resulting
hydroquinone inhibits both 5-lipoxygenase activity and lipid
peroxidation on the basis of its antioxidant ability (Ohkawa
et al., 199lb) by reducing the ferric iron in the active site of
the enzyme to the ferrous (resting state). Studies on the
metabolism of CV-6504 by mice, rats, dogs and monkeys
indicate reduction of the quinone ring and subsequent
conjugation to yield the 1- and 4-glucuronides and the
corresponding sulphates (Takeda Chemical Co., personal
communication). These conjugates would not be capable of
inhibiting 5-lipoxygenase by the suggested mechanism.
In the present study the tumour and tissue levels of CV-
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6504 and its glucuronide and sulphate metabolites have been
determined after single and consecutive dosing of mice
bearing the MAC16 adenocarcinoma. A comparison has
also been made between CV-6504 and its glucuronide and
sulphate metabolites on tumour growth and metabolism of
AA along the lipoxygenase pathways with a view to
establishing the mechanism of the anti-tumour effect.
Material and methods
Pure strain NMRI mice were obtained from our own
breeding colony and were fed a rat and mouse breeding
diet (Pilsbury's, Birmingham) and water ad libitum. Male
animals weighing 20-25 g were transplanted subcutaneously
with 1-2 mm3 fragments of the MAC16 or MAC13 tumours
by trocar into the right flank. The experiments were initiated
when the tumour volume, calculated from the formula:
length x (width)2
2
was between 72 and 128 mm3. Tumour dimensions were
measured by calipers. Mice bearing the MAC13 tumour were
subject to restricted randomisation into groups of nine to
receive either CV-6504 (5 mg kg-') or the 1- or 4-
glucuronide, or the 1- or 4-sulphate (50 mg kg-'). CV-6504
and the sulphate and glucuronide metabolites were supplied
by Takeda Chemical Industries Ltd., Osaka, Japan and were
administered p.o. daily in aqueous solution (0.1 ml). Control
animals received water alone (0.1 ml). Animals were
sacrificed if the tumour ulcerated, weight loss reached 25 to
30% of the original body weight (for the MAC16 tumour),
the tumour weight reached 10% of the host weight, or the
animals became moribund, as agreed by the Co-ordinating
Committee on Cancer Research of the UK for the welfare of
animals with neoplasms.
Evaluation ofmetabolism of CV-6504 in mice bearing the
MAC16 tumour
Mice bearing the MAC16 tumour were selected to have
tumour volumes above 240 mm3 and were administered [14C]Metabolism of CV-6504
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CV-6504 (specific activity 41.9 ,uCi mg-'; supplied by Takeda
Chemical Industries Ltd., Japan) at a dose level of
10 mg kg-' orally in water. At times 15 min, 30 min, 2 h
and 24 h after dosing, blood was removed from animals
under anaesthesia, with a mixture of halothane, oxygen and
nitrous oxide, by cardiac puncture using a heparinised
syr-inge. Plasma was prepared by centrifuging whole blood
in a Beckman microfuge for 30 s. The tumour, liver and
kidneys were removed from the carcase. In a second
experiment, mice bearing the MAC16 tumour (72-
128 mm3) were treated with [14C] CV-6504 (10 mg kg-')
daily for 6 days. On the seventh day plasma, liver, tumour
and kidney samples were taken as above 24 h after the final
dose.
Plasma samples for each time point were pooled. Tumour,
liver and kidney samples were homogenised in ice-cold
distilled water to form a 20% (weight:volume) homogenate.
Plasma and homogenates were adjusted to pH 6.0 with 1 N
hydrochloric acid. The samples were divided into two halves.
One half was treated with an equal volume of 10% f,-
glucuronidase (from Helix Pomatia; Sigma Chemical Co.
Ltd., Dorset, UK) and incubated for 16 h at 37°C. All
samples were extracted by addition of 5 volumes of methanol
and were centrifuged at 3000 x g for 10 min. The supernatant
was removed and evaporated to dryness under nitrogen (less
than 40°C) and redissolved in methanol (100 ,ul). Metabolites
and unchanged CV-6504 were separated by thin layer
chromatography (TLC) on silica GF254 using ethyl acetate-
methanol-acetic acid (50:10:1). Spots were visualised under
ultraviolet light at 254 nm and their identity confirmed by
standards run on the same plate. Unchanged CV-6504 or
hydrolysed glucuronides were separated from sulphates. The
concentration of CV-6504 and metabolites as determined by
measurement of the [14C] in each of the spots on the TLC
plate. Samples of silica were suspended in Optiphase HiSafe
11 and the radioactivity was determined using a 2000 CA Tri-
Carb liquid scintillation analyser.
Analysis of lipoxygenase metabolites of arachidonate
Animals bearing the MAC13 tumour were sacrificed by
cervical dislocation, the tumours removed immediately and
homogenised in RPMI-1640 containing 10% fetal calf serum
(FCS). The cells were washed in the same medium and
resuspended at 5 x 105 cells ml-'. They were incubated at
37°C in a humid atmosphere of 5% carbon dioxide in air
Table I Metabolism of CV-6504 in mice bearing the MAC16 tumour
CV-6504
Unknown
0.75 ± 0.20
(4±1)
1.17±0.37
(6±2)
0.57 ±0.07
(15 ±3)
0.02 ± 0
(25 ±4)
0.21 ± 0.09
(16 ± 6)
0.22 0.04**
(4 1)
0.60±0.01**
(14± 1)
0.26 ± 0.02**
(23 ± 2)
0.10 ± 0.01
(29 ± 1)
0.42 ± 0.13*
(16 ± 5)
0.66 ±0.10
(5 1)
0.65 ±0.12**
(6 1)
0.16±0.03**
(9± 1)
0.04±0.00
(25 ±4)
0.33 t0.04
(11 2)
0.16±0.01**
(4 1)
0.09 0.05**
(1±i1)
0.02 0.00**
(4± 1)
0.02 0.00
(3 1)
ND
CV-6504
Sulphate
1.70 ± 0.25
(9 ± 2)
2.38 ± 0.36
(12 ± 3)
0.57 ± 0.07
(18 ± 2)
0.03 ±0
(28 ± 2)
0.20 ± 0.03
(15 ± 2)
0.32 ± 0.04**
(7 1)
0.50 0.01
(14±1)
0.22 ± 0.02
(22 ±2)
0.12 ± 0.02
(31 ±1)
0.44± 0.08
(17 ± 3)
0.42 ±0.13**
(7 ±2)
0.94 0.06**
(6 2)
0.29 0.03
(13 2)
0.05 ± 0.00
(28 ± 2)
0.55 ± 0.08
(13 ± 2)
0.14± 0.08
(4 ±2)
0.38 0.20
(6 3)
0.11I0.07*
(7 3)
0.03 0.02
(7 3)
0.13 0.00
(6 0)
CV-6504
Glucuronide
11.25 ± 0.38
(61± 3)
15.27 ± 0.38
(69 ± 4)
1.73 ± 0.18
(55± 5)
0.04 ±0
(28 ± 2)
0.67 ± 0.08
(50± 6)
2.36 ± 0.04**
(74± 1)
2.00 ± 0.20
(47 ±4)
0.35 ± 0.03
(31 ± 3)
0.10 ± 0.01
(25±1)
1.20 ± 0.13
(46 ± 5)
8.28 ±0.13
(80 ± 2)
13.03 ± 0.07
(83 ± 2)
1.95 ± 0.07
(70 ± 3)
0.05 ± 0.00
(31 ± 1)
2.90 ± 0.17
(64 ±4)
5.09 ± 1.55
(90 ± 3)
4.85± 1.19
(90 ± 6)
0.73 ± 0.20
(90 ± 2)
0.31 ±0.07
(89 ± 3)
1.87 ± 0.25
(97 ± 3)
CV-6504
Unchanged
4.80±0.30
(26± 3)
2.97 ± 0.66
(14±4)
0.37 ± 0.04
(13 ±4)
0.04 ± 0.00
(30±2)
0.25 ± 0.88
(19 ±6)
0.28 0.08**
(9 2)
1.20±0.10**
(28 3)
0.28 0.05
(25 3)
0.55 ± 0.13**
(21 ± 5)
0.56 ± 0.12**
(21 ± 5)
0.66±0.10**
(8 1)
1.06 i0.06**
(7 2)
0.23 0.04
(11±2)
0.02 ±0
(15 ± 0)
0.46 ± 0.04
(8 2)
0.20 0.05**
(3 1)
0.14±0.07**
(2 1)
0.01 ±0.00**
(1i0)
0.01 ± 0.00
(1±0)
0.01 0.00*
(1i 1)
Time
Liver
0.25
0.50
2.00
24.00
24.00c
Tumour
0.25
0.50
2.00
24.00
24.OO3
Kidney
0.25
0.50
2.00
24.00
24.OOa
Plasma
0.25
0.50
2.00
24.00
24.00a
Total
18.50 ±0.29
21.58 ±0.69
3.12 ±0.10
0.14 ±0.04
1.33 ± 0.32
3.18 ± 0.42**
4.20 ±0.80**
1.12 ± 0.15
0.87 ±0.10
2.60 ±0.10
10.07± 1.04**
15.64 ±0.83**
2.61 ±0.17
0.16+0.02
4.20 ±0.10
6.72 + 3.08**
5.47 ± 1.43**
0.85 ±0.26
0.35 ±0.09
1.94 ±0.09
Differences from liver samples are indicated by *P<0.05 and **P<0.01. The results are expressed asygml-' plasma (n =4) and ,Ig tissue (n =20).
Figures in parenthesis refer to the percentage occurrence of the various forms. aValues after six daily dosings with CV-6504. ND, none detected.Metabolism of CV-6504im
HJ Hussey and MJ Tisdale t
1351
120
- 100
= 80
60 2> 60
+1 40
0
20
a
,I 1 111 1111 11111 u0O.'
120
100
0-
,C
0
80
60
40
20
n
10 100
b
b b
II"
I'\\111 1 1 11 1
v
0.1 10 100
Concentration (gM)
Figure 1 The effect of CV-6504 (x) and (a) CV-6504-1-sulphate
(-) and 4-sulphate (0) and (b) CV-6504-1-glucuronide (0) and
4-glucuronide (0) on the growth of MAC13 in vitro after 72 h.
Differences a, P<0.01 and b, P<0.005 from the effect of CV-
6504 at the same concentration were determined by t-test with the
Bonferroni correction. The experiment was repeated nine times.
with 25 jCi [3H] AA together with unlabelled material to a
final concentration of 10 ,UM. A time course showed that
maximum radioactivity was recovered from the tumour cells
after 1 h incubation. Cells (5 x 106) were incubated with
10 jiM CV-6504 for 30 min and the metabolites (100 gM)
were incubated up to 2 h before the administration of the
[3H] AA. After the labelling stage was complete, the cells
were separated by low-speed centrifugation (1500 x g for
10 min) and were washed twice with phosphate-buffered
saline (PBS). They were then resuspended in ice-cold PBS
(0.8 ml) and sonicated for 3 x 15 s pulses with 10 s intervals
in between. The solution was then acidified to pH 3.5 with
1 N hydrochloric acid before suspension in chloroform-
methanol (1:2 v/v). The solution was vortexed for 1 min and
left for 30 min at room temperature. Chloroform (1 ml) was
then added, the solution vortexed for 10 s, followed by the
addition of ice-cold 0.001 N hydrochloric acid (1 ml) and
vortexing for another 10 s. After centrifugation at 2000 x g
for 20 min at 4°C, the chloroform layer was removed and the
aqueous phase was re-extracted with chloroform (2 ml). The
combined chloroform extracts were evaporated under a
stream of nitrogen and the residue was dissolved in
acetonitrile (100 lIl far UV HPLC grade). Samples could be
stored at -70°C under argon in the absence of light. Cell
lipids were analysed by reverse-phase high-performance liquid
chromatography (RP-HPLC) with a Waters ji Bondapak C18
column (3.9 x 300 mm) by an isocratic elution at 1.5 ml
min-' with 58% acetonitrile-water-acetic acid (20:100:0.5
v/v) and 42% acetonitrile-acetic acid (100:0.05 v/v) (Liu et
al., 1994a). Radioactivity and UV absorbance at 237 nm were
monitored. Peaks were identified based on the retention times
of authentic 5-, 11-, 12- and 15-HETE (Sigma Chemical Co.,
Poole, Dorset, UK). The amount of HETEs was quantified
based on the specific activity of radiolabelled AA and the
ratio of radiolabelled to unlabelled substrate.
Statistical analysis
Results are presented as means+s.e.m. The data were
statistically evaluated using two-way analysis of variance
followed by Tukey's test.
Results
The metabolism and pharmacokinetics ofCV-6504 after single
and consecutive doses of 10 mg kg-' in mice bearing the
MAC16 tumour has been determined by the recovery of ["4C]
CV-6504 from tissues and plasma. The concentration of CV-
6504 and its metabolites in liver, kidney, tumour and plasma
over a single 24 h period and six daily administrations is
shown in Table I. Peak plasma levels of CV-6504 were
observed at 0.25 h after administration. Free CV-6504 rapidly
disappeared from the plasma and tissues and there was an
accumulation of the sulphate and glucuronide, together with
unknown metabolites. The concentration of unchanged CV-
6504 and metabolites recovered from the tumour over the first
0.5 h of treatment was significantly lower than those found in
the liver and similar to that found in kidney. However, by 24 h
after a single administration or after six consecutive daily
doses, the concentration of free CV-6504 in the tumour was
significantly higher than the liver. The concentration of CV-
6504 in the MAC16 tumour (3.3 gIM) was equal to the
concentration causing 50% inhibition of growth in tissue
culture (3,iM), and, thus, sufficient to explain tumour
regression. In both liver and tumour the concentration of
CV-6504 glucuronides decreased with time, possibly owing to
metabolism by f,-glucuronidase. Measurement of enzyme
activity in tissue homogenates showed similar activity to fi-
glucuronidase in MAC16 tumour and liver (10.8 and 10.3 jug
phenolphthalein released from phenolphthalein glucuronide
per mg protein in 30 min at pH 6.8). This confirms that the
tumour has the ability to accumulate free CV-6504 by
hydrolysis of the glucuronide conjugate.
The effect of CV-6504, the 1- and 4-glucuronide and the l-
and 4-sulphate metabolites on growth of the MAC13 cells in
vitro is shown in Figure 1. While free CV-6504 effectively
inhibited cell growth with an IC50 value of 3 gM, none of the
metabolites were effective growth inhibitors at concentrations
up to 100 pLM. The effect of the four metabolites and free CV-
6504 on the growth of the MAC13 tumour in vivo is shown in
Figure 2 (a and b). When administered daily at a dose of
50 mg kg-', the anti-tumour activity of the glucuronide and
sulphate conjugates was similar to that obtained with free
CV-6504 administered orally at 5 mg kg-1 day-'. The anti-
tumour activity of the 4-glucuronide and 1-sulphate was
slightly reduced in comparison with the 1-glucuronide and 4-
sulphate, although this was not significant. This suggests that
the MAC13 tumour may also be capable of enzymatic
deconjugation of the glucuronide and sulphate metabolites.
Broken cell preparations of the MAC13 tumour were capable
of liberating 18 jug phenolphthalein per 30 min per mg
protein from 0.4 mm phenolphthalein glucuronide and
30 nmol sulphate per 30 min per mg protein from 1.78 mM
p-nitrocatechol sulphate at pH 5.0. Thus anti-tumour activity
might be expected to be higher in those tumours expressing
glucuronidase and sulphatase.
The effect of CV-6504 and the 1-sulphate and 4-
glucuronide metabolites on the metabolism of AA in
MAC13 tumours ex vivo is shown in Figure 3 (a and b).
There was rapid metabolism of AA with fairly equal
distribution along the pathways leading to the formation of
5-, 11-, 12- and 15-hydroxyeicosatetraenoic acids (HETEs).
After incubation with 10 jiM CV-6504 for 30 m-, 5-, 11-, 12-
and 15-HETE production, as well as the total unmetabolised
AA, was significantly decreased. The percentage reduction in
formation of 12- and 15-HETE exceeded that of 5-HETE. At
a concentration of 100 jiM, CV-6504 1-sulphate significantly
reduced production of 12- and 15-HETE after 30 min, 11-
HETE after 1 h and 5-HETE after 2 h. Incubation with
r-
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Figure 2 The effect of CV-6504 (5 mg kg- ' day-1; x) and (a)
CV-6504-1-sulphate (I) and 4-sulphate (0) and (b) CV-6504-1-
glucuronide (0) and 4-glucuronide (0) all at 50 mg kg-l day'-
on the growth of the MAC13 tumour in vivo. Differences from
control (El) values are indicated as a, P<0.05 and b, P<0.01,
while c, P<0.05 from the group treated with CV-6504.
100 gM CV-6504 4-glucuronide also significantly reduced 5-,
11- and 12-HETE production by 30 min and 15-HETE
production by 1 h.
Discussion
We have previously shown CV-6504 to exert marked anti-
tumour activity in the murine tumour models, MAC16 and
MAC13, passaged in NMRI mice (Hussey et al., 1996). CV-
6504 is known to be rapidly removed from the circulation
and converted into the glucuronide and sulphate conjugates,
which are not effective lipoxygenase inhibitors and might not
be expected to exert anti-tumour activity. It was, therefore,
important to determine the rate and extent of formation of
these metabolites in the murine model. After oral adminis-
tration of [14C] CV-6504, both free drug and metabolites were
accumulated within the MAC16 tumour 2 h after adminis-
tration. In comparison with liver, there was a significantly
increased level of unmetabolised CV-6504 recovered per gram
of tumour, which was at a concentration sufficient to account
for the growth inhibition observed. At 24 h after oral dosing
and after consecutive daily dosing, the relative concentration
of unmetabolised to metabolised drug was increased, which
was evident in the reduced percentage of glucuronide
metabolites recovered. The glucuronide and sulphate con-
jugates of CV-6504 can be metabolised to free drug by the
action of fl-glucuronidase and sulphatase. Although the
glucuronide and sulphate conjugates were ineffective in
inhibiting the growth of the MAC13 tumour in vitro, they
were as effective as CV-6504 in vivo, when used at a
concentration five times higher. Both the MAC16 and
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Figure 3 The effect of CV-6504 (10 gM, 30 min; _) and CV-
6504-1-sulphate (a) (100 pM) or CV-6504-4-glucuronide (b)
(100 yM) on the metabolism of AA to HETEs in the MAC13
tumour. Cells were untreated (E3) or treated with the
metabolites for 30 min (E ), 1 h (L) or 2 h (m). The
experiment was repeated four times. Differences from controls are
indicated as a, P<0.01 and b, P<0.05.
MAC13 tumours possessed fl-glucuronidase and sulphatase
at levels similar to that found in the liver. This suggests a role
for these enzymes in the anti-tumour action of CV-6504. A
similar activation was observed for aniline mustard, which
was metabolised to a glucuronide conjugate and was most
active in tumours possessing fl-glucuronidase activity
(Connors and Whisson, 1966). Both fl-glucuronidase and
sulphatase are more active at lower pH values, which may be
attained in solid tumours. A low pH would also facilitate
uptake of the glucuronide conjugate into the cell by
suppressing the ionisation of the carboxyl group.
Arachidonic acid can be oxygenated by a family of non-
haem iron-containing dioxygenases-the lipoxygenases. The
major mammalian enzymes are the 5-, 12- and 15-
lipoxygenases, which form the corresponding 5-, 12- and
15-HETE. Both 12- and 15-HETE have been implicated in
the stimulation of DNA synthesis and cell growth in fetal
bovine aortic endothelial cells (Setty et al., 1987), which is
mediated by inhibition of diacyl glycerol kinase and the
concomitant accumulation of cellular diacylglycerol. 12(S)-
HETE has also been shown to promote wound healing of
injured microvascular endothelial cells by increasing DNA
synthesis more than 4-fold (Tang et al., 1995). In neonatal rat
lens epithelial cells it has been suggested that 12(S)-HETE
may mediate EGF/insulin-stimulated DNA synthesis by
regulating protooncogene expression (Lysz et al., 1994), and
that it may augment the invasiveness of rat prostatic tumour
b
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cells through selective activation of protein kinase C, (Liu et
al., 1994b). Thus, inhibition of 12- and/or 15-HETE
formation may be expected to inhibit tumour cell growth
and metastasis.
In the present study, CV-6504 has been shown to inhibit
the production of 5-, 12- and 15-HETE in MAC13 tumour
cells ex vivo. Both the 12- and 15-lipoxygenase pathways are
inhibited, despite the targeting of this compound to 5-
lipoxygenase (Ohkawa et al., 1991a), and the inhibitory effect
on 12- and 15-lipoxygenase exceeded that of 5-lipoxygenase
as measured by HETE formation. A similar effect has been
observed with the PUFA eicosapentaenoic acid (EPA), which
also exerts a marked antiproliferative effect on the
chemounresponsive MAC16 tumour (Hudson et al., 1993).
This agent has also been shown to exert an anti-tumour effect
against human breast cancer cells xenotransplanted into nude
mice by reducing the tumour concentration of 12- and 15-
HETE, while the level of 5-HETE was unaffected (Rose et
al., 1995). Both CV-6504 1-sulphate and 4-glucuronide
inhibited formation of 5-, 12- and 15-HETE formation in
MAC13 tumour cells ex vivo in a time-dependent manner,
suggesting conversion of these metabolites to free CV-6504.
Inhibition of 12- and 15-HETE production occurred before
inhibition of 5-HETE production. Thus, suppression of 12-
and/or 15-lipoxygenase pathways may be most important for
inhibition of tumour growth.
These results suggest that CV-6504 may inhibit tumour
growth as a result of the ability to inhibit 12- and/or 15-
HETE production. Human tumours with a dependence on
the 12- and 15-lipoxygenase pathways for growth may also be
sensitive to this agent.
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